Effects of tolvaptan on dyspnoea relief from the EVEREST trials
Article 2009 en
Authors
PP
Peter S. Pang
MK
Marvin A. Konstam
HK
H. B. Krasa
Abstract
1 min read
Post hoc analysis suggests that tolvaptan modestly improves dyspnoea compared with standard therapy alone, regardless if given early or relatively late after hospitalization, and also across major pre-specified subgroups, despite ongoing background therapy aimed at relieving signs and symptoms. Significant variability around when dyspnoea was assessed, in addition to the persistence of dyspnoea despite ongoing background therapy, may influence how future clinical trials assess dyspnoea in acute heart failure syndromes.
Mihai Gheorghiade, Peter S. Pang, John E. Blair, Karl Swedberg, Faı̈ez Zannad, Aldo Maggioni, L Grinfield, J. C. Burnett, Christopher Zimmer, Marvin A. Konstam
Hassan Khan, Andreas P. Kalogeropoulos, Andrew P. Ambrosy, Aldo Maggioni, Faı̈ez Zannad, Marvin A. Konstam, Karl Swedberg, Clyde W. Yancy, Gregg C. Fonarow, Mihai Gheorghiade, Javed Butler
Carlo Ferri Marini, Davide Sisti, James S. Skinner, Mark A. Sarzynski, Claude Bouchard, Stefano Amatori, Marco Rocchi, Giovanni Piccoli, Vilberto Stocchi, Ario Federici, Francesco Lucertini
Stephen J. Greene, Gregg C. Fonarow, Scott D. Solomon, Haris Subačius, Muthiah Vaduganathan, Andrew P. Ambrosy, Marat Fudim, Michael Böhm, Aldo Maggioni, Eldrin F. Lewis, Faı̈ez Zannad, Javed Butler
Jonas Hallén, Aldo Maggioni, Esteban López de Sá, Fabio Maria Turazza, Klaus K. Witte, Erland Erdmann, Ulf Dahlström, Georg Ertl, Olav Wendelboe Nielsen, J. López Sendón, Thomas Holbro, Chien‐Wei Chen, Claudio Gimpelewicz, Martín Cowie
Discussion(0)
No comments yet. Be the first to comment.